Stock events for Sagimet Biosciences, Inc. (SGMT)
Over the past six months, Sagimet Biosciences' stock has experienced fluctuations, including a significant increase and a drop following an earnings announcement. The company announced positive Phase 1 pharmacokinetic results for a combination therapy and its license partner announced the acceptance of a New Drug Application for denifanstat in China. Analysts have a consensus rating of "Moderate Buy" for SGMT, with an average 12-month price target of $26.00.
Demand Seasonality affecting Sagimet Biosciences, Inc.’s stock price
There is no explicit information available regarding demand seasonality for Sagimet Biosciences, Inc.'s products or services. Its revenue generation is primarily tied to research and development milestones, potential licensing agreements, and eventual commercialization of its drug candidates, rather than seasonal consumer demand patterns.
Overview of Sagimet Biosciences, Inc.’s business
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics, specifically selective fatty acid synthase (FASN) inhibitors. Their lead drug candidate, denifanstat, is in development for MASH and acne and has received Breakthrough Therapy designation from the FDA for non-cirrhotic MASH with moderate to advanced liver fibrosis. The company is also developing a second oral FASN inhibitor, TVB-3567, which is in a Phase 1 trial for acne and potential cancer applications.
SGMT’s Geographic footprint
Sagimet Biosciences, Inc. is headquartered in San Mateo, California, United States. Denifanstat is also being tested in China by Ascletis BioScience Co. Ltd.
SGMT Corporate Image Assessment
Sagimet Biosciences' brand reputation is influenced by its clinical development progress and regulatory milestones. Positive news, such as the acceptance of a New Drug Application for denifanstat in China and positive Phase 1 clinical trial results, contribute positively to its reputation. Analyst coverage generally reflects a "Moderate Buy" consensus.
Ownership
Sagimet Biosciences Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 44.27% of the company, while Sagimet Biosciences insiders own 67.53%. Retail investors hold 46% of the company. Patrick J. Kerins is the largest individual shareholder, owning 9.27% of the company.
